Vinorelbine

Vinorelbine

By Sagent Pharmaceutical, Inc. | Last revised: 1 September 2009

Vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (NSCLC). In patients with Stage IV NSCLC, vinorelbine is indicated…

Vinorelbine

Vinorelbine

By Pfizer Laboratories Div Pfizer Inc. | Last revised: 8 March 2013

Vinorelbine Injection USP. is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC). In patients with Stage IV NSCLC…

VINORELBINE TARTRATE

Vinorelbine Tartrate

By Pierre Fabre Médicament | Last revised: 17 August 2011

VINORELBINE. is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC). In patients with Stage IV NSCLC. VINORELBINE. is…

Vinorelbine Tartrate

Vinorelbine Tartrate

By Sandoz Inc. | Last revised: 19 September 2011

Vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC). In patients with Stage IV NSCLC, vinorelbine is indicated…

NAVELBINE

Vinorelbine Tartrate

By Pierre Fabre Médicament | Last revised: 2 February 2012

NAVELBINE. is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC). In patients with Stage IV NSCLC. NAVELBINE. is indicated…